NSE: MANKIND · 16 October 2026 · Pre-market update
- Mankind Pharma Limited is in focus ahead of the market open following its board's approval to acquire a 70% stake in Belgium-based Armed Cell Therapeutics B.V. via its subsidiary. The strategic move marks the company's entry into next-generation CAR-T therapies for cancer. Additionally, the company received an ESG rating of 71 from NSE Sustainability Ratings and Analytics Limited.
- Mankind Pharma's board approved an additional investment of up to EUR 45 million in its wholly-owned subsidiary, Mankind Netherlands B.V., taking the aggregate investment limit to EUR 50 million. This capital will be utilized to invest EUR 48 million in installments to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a biotechnology company developing next-generation CAR-T cell therapies for cancer with lead programs in non-Hodgkin lymphoma and small cell lung cancer.
- Trading volume was 1.07 times the 20-day average daily volume.
Mankind Pharma Company News Before Market Open
Mankind Pharma Limited is in focus ahead of the market open following its board's approval to acquire a 70% stake in Belgium-based Armed Cell Therapeutics B.V. via its subsidiary. The strategic move marks the company's entry into next-generation CAR-T therapies for cancer. Additionally, the company received an ESG rating of 71 from NSE Sustainability Ratings and Analytics Limited.
The acquisition of a majority stake in Armed Cell Therapeutics broadens Mankind Pharma's technological footprint into advanced global oncology research. The planned EUR 48 million investment underlines the company's capital allocation towards specialized therapeutic segments outside its core domestic formulations. Technical baseline: The stock closed the previous trading day on October 15, 2026, at ₹2,347.60, up 0.54%, trading within a prior day range of ₹2,321.10 to ₹2,365.00.
6.45 lakh shares traded on 15 October 2026. This compares with a 20-day average daily volume of 6.03 lakh shares (1.07 times). The five-day average daily volume was 4.25 lakh shares.
The acquisition of a majority stake in Armed Cell Therapeutics broadens Mankind Pharma's technological footprint into advanced global oncology research. The planned EUR 48 million investment underlines the company's capital allocation towards specialized therapeutic segments outside its core domestic formulations. Technical baseline: The stock closed the previous trading day on October 15, 2026, at ₹2,347.60, up 0.54%, trading within a prior day range of ₹2,321.10 to ₹2,365.00.
Latest Company Developments
Mankind Pharma's board approved an additional investment of up to EUR 45 million in its wholly-owned subsidiary, Mankind Netherlands B.V., taking the aggregate investment limit to EUR 50 million. This capital will be utilized to invest EUR 48 million in installments to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a biotechnology company developing next-generation CAR-T cell therapies for cancer with lead programs in non-Hodgkin lymphoma and small cell lung cancer.
This acquisition represents a strategic entry into cutting-edge oncology and next-generation CAR-T cell therapies, aligning with the company's long-term goal of building a global innovation-led pharmaceutical business.
NSE Sustainability Ratings and Analytics Limited independently assigned an Environmental, Social, and Governance (ESG) rating of '71' to Mankind Pharma for FY26, based on publicly available information without prior engagement by the company.
Provides investors with an independent benchmark of the company's ESG practices and sustainability transparency.
a press release dated October 15, 2026, titled "Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies ".
Outcome of Board Meeting held on October 15, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 10.87% on 30 June 2026. This compares with 10.36% on 31 March 2026, a change of +0.51 percentage points.
The filing reported 36 MF/UTI holders.
What to Watch Next
- Market sentiment and opening price action following the announcement of the cross-border acquisition and ESG rating.
- Management commentary regarding the timelines for completing the definitive agreements and funding tranches for ACTx.
- Volume participation and relative performance compared to the broader pharmaceutical sector at the market open.
Other Dated Coverage
- Mankind Pharma Share Price Today: Why MANKIND Is Falling 2.47% | 14 October 2026 — 14 October 2026
- Why Mankind Pharma Shares Fell 2.21% Today: Sector Weakness & Context | 5 October 2026 — 5 October 2026
- Why Mankind Pharma Shares Are Down 2.36% Today | 1 October 2026 — 1 October 2026
More Mankind Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Mankind Pharma company news?
Mankind Pharma's board approved an additional investment of up to EUR 45 million in its wholly-owned subsidiary, Mankind Netherlands B.V., taking the aggregate investment limit to EUR 50 million. This capital will be utilized to invest EUR 48 million in installments to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a biotechnology company developing next-generation CAR-T cell therapies for cancer with lead programs in non-Hodgkin lymphoma and small cell lung cancer.
How strong was Mankind Pharma’s trading volume?
6.45 lakh shares traded, 1.07 times the 20-day average daily volume. The price and volume data are dated 15 October 2026.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.